Effects of pulse methylprednisolone and oral methylprednisolone treatments on serum levels of oxidative stress markers in Graves' ophthalmopathy

被引:32
作者
Akarsu, Ersin [2 ]
Buyukhatipoglu, Hakan [1 ]
Aktaran, Sebnem [2 ]
Kurtul, Naciye [3 ]
机构
[1] Harran Univ Sch Med, Dept Internal Med, Sanliurfa, Turkey
[2] Gaziantep Univ Sch Med, Dept Endocrinol, Gaziantep, Turkey
[3] Kahramanmaras Univ Sch Sci, Dept Chem, Kahramanmaras, Turkey
关键词
FREE-RADICALS; DISEASE; METHIMAZOLE; MANAGEMENT; HYPERTHYROIDISM; PATHOGENESIS; MECHANISMS; THERAPY; SMOKING;
D O I
10.1111/j.1365-2265.2010.03904.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Recent evidence has shown that oxidative stress may play a role in the pathogenesis of autoimmune diseases, and this is an issue of considerable research interest in the field of infiltrative ophthalmopathy. Therefore, we evaluated both the relationship between Graves' ophthalmopathy (GO) and serum levels of certain indicators of oxidative stress, and the effects of methylprednisolone treatment on serum malondialdehyde (MDA) and glutathione (GSH) levels in patients with euthyroid GO. Materials and Methods We compared GO patients to both Graves' patients without ophthalmopathy and healthy controls. Ultimately, we assessed four subject groups. Graves' patients with ophthalmopathy (GO) were subcategorized into two groups: Group A subjects (n = 18) were given intravenous glucocorticoid and Group B patients (n = 15) were given oral glucocorticoid. Graves' patients without ophthalmopathy comprised Group C (n = 20), and healthy controls comprised Group D (n = 15). Serum levels of MDA and GSH were measured at baseline and after 4 and 24 weeks of observation via spectrophotometric methods. Results We found that serum MDA levels were significantly higher in the two GO groups (Groups A and B) than in GO patients without ophthalmopathy or healthy controls. Conversely, GSH levels were significantly lower in the two GO groups than in Groups C and D. MDA and GSH levels were not different between the latter two groups. MDA levels were strongly and positively correlated with a clinical activity score (CAS). In Group A, MDA levels and the CAS were significantly lower than in Group B at 4 weeks. After 24 weeks, however, MDA levels and the CAS were similar in these two groups. Conclusion Oxidative stress appears to be involved in the pathophysiology of GO. Relative to oral dosing, the intravenous administration of a glucocorticoid seems to yield more rapid improvement in disease activity. MDA might be useful as an indicator of clinical activity.
引用
收藏
页码:118 / 124
页数:7
相关论文
共 31 条
[1]   Peripheral parameters of oxidative stress in Graves' disease: the effects of methimazole and 131 iodine treatments [J].
Abalovich, M ;
Llesuy, S ;
Gutierrez, S ;
Repetto, M .
CLINICAL ENDOCRINOLOGY, 2003, 59 (03) :321-327
[2]   The effect of methimazole on the oxidant and antioxidant system in patients with hyperthyroidism [J].
Ademoglu, E ;
Gokkusu, C ;
Yarman, S ;
Azizlerli, H .
PHARMACOLOGICAL RESEARCH, 1998, 38 (02) :93-96
[3]   Comparison of intravenous methylprednisolone therapy vs. oral methylprednisolone therapy in patients with Graves' ophthalmopathy [J].
Aktaran, S. ;
Akarsu, E. ;
Erbagci, I. ;
Araz, M. ;
Okumus, S. ;
Kartal, M. .
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2007, 61 (01) :45-51
[4]   CHOICE OF THERAPY AND CRITERIA FOR ASSESSING TREATMENT OUTCOME IN THYROID-ASSOCIATED OPHTHALMOPATHY [J].
BAHN, RS ;
GORMAN, CA .
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 1987, 16 (02) :391-407
[5]  
BAHN RS, 1993, NEW ENGL J MED, V329, P1468
[6]   Management of Graves' ophthalmopathy: Reality and perspectives [J].
Bartalena, L ;
Pinchera, A ;
Marcocci, C .
ENDOCRINE REVIEWS, 2000, 21 (02) :168-199
[7]   Editorial: Glucocorticoids for Graves' ophthalmopathy: How and when [J].
Bartalena, L .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (09) :5497-5499
[8]   MORE ON SMOKING-HABITS AND GRAVES OPHTHALMOPATHY [J].
BARTALENA, L ;
MARTINO, E ;
MARCOCCI, C ;
BOGAZZI, F ;
PANICUCCI, M ;
VELLUZZI, F ;
LOVISELLI, A ;
PINCHERA, A .
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 1989, 12 (10) :733-737
[9]   Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO [J].
Bartalena, Luigi ;
Baldeschi, Lelio ;
Dickinson, Alison ;
Eckstein, Anja ;
Kendall-Taylor, Pat ;
Marcocci, Claudio ;
Mourits, Maarten ;
Perros, Petros ;
Boboridis, Kostas ;
Boschi, Antonella ;
Curro, Nicola ;
Daumerie, Chantal ;
Kahaly, George J. ;
Krassas, Gerasimos E. ;
Lane, Carol M. ;
Lazarus, John H. ;
Marino, Michele ;
Nardi, Marco ;
Neoh, Christopher ;
Orgiazzi, Jacques ;
Pearce, Simon ;
Pinchera, Aldo ;
Pitz, Susanne ;
Salvi, Mario ;
Sivelli, Paolo ;
Stahl, Matthias ;
von Arx, Georg ;
Wiersinga, Wilmar M. .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2008, 158 (03) :273-285
[10]  
BEDRANEK J, 2005, CLIN BIOCHEM, V38, P13